Price
Target price
€0.003
€0.003
-
-
-
-
06.12.23 / Stuttgart Stock Exchange
WKN: A2PJ6N / Name: Advanced / Stock / Biotechnology & Medical Research / Micro Cap /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Advanced
sharewise wants to provide you with the best news and tools for Advanced, so we directly link to the best financial data sources.
Financials
News
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
Key Points
- Interested in PTC Therapeutics, Inc.? Here are five stocks we like better.
- PTC Therapeutics plans to acquire ST-920, a one-time Fabry disease gene therapy, through a competitive
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Key Points
- Interested in Ocugen, Inc.? Here are five stocks we like better.
- Ocugen is targeting 2027 BLA filings for its OCU400 retinitis pigmentosa and OCU410ST Stargardt disease gene
JFrog Says AI Software Boom, Cloud Demand and Security Adoption Are Fueling Growth
Key Points
- Interested in JFrog Ltd.? Here are five stocks we like better.
- JFrog reported strong growth, including 29% overall revenue growth and 53% cloud-revenue growth, driven by higher
Lumexa Imaging Q2 Earnings Call Highlights
Key Points
- Interested in Lumexa Imaging Holdings, Inc.? Here are five stocks we like better.
- Lumexa returned to profitability in Q2: Revenue rose 5.1% year over year to $264.2 million, net
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
Key Points
- Interested in Candel Therapeutics, Inc.? Here are five stocks we like better.
- Candel Therapeutics plans to submit a biologics license application by the end of 2026 for aglatimagene
Spectral AI Q2 Earnings Call Highlights
Key Points
- Interested in Spectral AI, Inc.? Here are five stocks we like better.
- FDA clearance is shifting Spectral AI toward commercialization: The company plans a disciplined U.S. and
NORMA Group Q2 Earnings Call Highlights
Key Points
- Interested in NORMA Group SE? Here are five stocks we like better.
- Profitability improved despite weak automotive demand: Q2 adjusted EBIT rose to EUR 7.6 million from EUR 2.3
Lundin Mining Q2 Earnings Call Highlights
Key Points
- Interested in Lundin Mining Co.? Here are five stocks we like better.
- Lundin Mining delivered strong Q2 results, with revenue above $1.2 billion, adjusted EBITDA of $658 million and
Advanced Drainage Systems Q1 Earnings Call Highlights
Key Points
- Interested in Advanced Drainage Systems, Inc.? Here are five stocks we like better.
- Record first-quarter performance: Fiscal 2027 net sales reached $1 billion, up 21% year over
Smith & Nephew SNATS Q2 Earnings Call Highlights
Key Points
- Interested in Smith & Nephew SNATS, Inc.? Here are five stocks we like better.
- Smith & Nephew cut its 2026 underlying revenue-growth outlook to about 4% after second-quarter growth
Solventum Q2 Earnings Call Highlights
Key Points
- Interested in Solventum Corporation? Here are five stocks we like better.
- Second-quarter results exceeded expectations: Sales reached $2.2 billion, with organic growth of 9.5%, while
Rayonier Advanced Materials Q2 Earnings Call Highlights
Key Points
- Interested in Rayonier Advanced Materials Inc.? Here are five stocks we like better.
- Strategic review remains active: CEO Dan Krawczyk said the process is progressing with urgency and
Onto Innovation Q2 Earnings Call Highlights
Key Points
- Interested in Onto Innovation Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Revenue rose 35% year over year to $343 million, while non-GAAP EPS of
Mativ Q2 Earnings Call Highlights
Key Points
- Interested in Mativ Holdings, Inc.? Here are five stocks we like better.
- Mativ delivered record profitability in Q2 2026: Adjusted EBITDA rose nearly 12% to $75 million, with margin
Emergent Biosolutions Q2 Earnings Call Highlights
Key Points
- Interested in Emergent Biosolutions Inc.? Here are five stocks we like better.
- Q2 performance exceeded expectations: Revenue reached $234 million and adjusted EBITDA rose to $97
BlackSky Technology Q2 Earnings Call Highlights
Key Points
- Interested in BlackSky Technology Inc.? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 50% year over year to $33.3 million, while adjusted EBITDA reached
ATI Q2 Earnings Call Highlights
Key Points
- Interested in ATI Inc.? Here are five stocks we like better.
- ATI exceeded its second-quarter outlook, with revenue up 11% year over year to $1.3 billion and adjusted EBITDA up 37% to
LANXESS Aktiengesellschaft Q2 Earnings Call Highlights
Key Points
- Interested in LANXESS Aktiengesellschaft? Here are five stocks we like better.
- Second-quarter performance improved sharply: Sales rose 13% sequentially and EBITDA increased 62%
Organogenesis Q2 Earnings Call Highlights
Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for
Nova Q2 Earnings Call Highlights
Nova (NASDAQ:NVMI) reported record second-quarter revenue of $255 million, up 8% sequentially and 16% from a year earlier, as demand
nLight Q2 Earnings Call Highlights
Key Points
- Interested in nLight? Here are five stocks we like better.
- nLight reported record second-quarter results: Revenue rose 34% year over year to $82.6 million, product revenue increased
Kulicke and Soffa Industries Q3 Earnings Call Highlights
Key Points
- Interested in Kulicke and Soffa Industries, Inc.? Here are five stocks we like better.
- Strong fiscal third-quarter performance: Revenue rose 36.2% sequentially and 123% year over
Morgan Advanced Materials H1 Earnings Call Highlights
Key Points
- Interested in Morgan Advanced Materials plc? Here are five stocks we like better.
- First-half revenue rose 4.8% organically to £518 million, while adjusted operating profit reached
Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares Q2 Earnings Call Highlights
Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares (NASDAQ:XNDU) reported second-quarter revenue of CAD 1.5
Enpro Q2 Earnings Call Highlights
Key Points
- Interested in Enpro Inc.? Here are five stocks we like better.
- Strong second-quarter performance: Sales rose 17.6% year over year to $338.8 million, while adjusted EBITDA increased